Allopathy
Prescription Required
DCGI (Drugs Controller General of India)
Schedule H
Ligelizumab belongs to the Anti-Immunologlobulin E Antibody Pharmacological class.
Ligelizumab is approved for the treatment of Chronic Spontaneous Urticaria.
Ligelizumab binds to IgE and hence prevents binding of IgE to FcRI i.e. high-affinity IgE receptor, on the basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the cascade of allergic reactions.
Ligelizumab hence leads to relief from Chronic Spontaneous Urticaria.
Ligelizumab can be used in the treatment of:
- Chronic Spontaneous Urticaria
Ligelizumab can help to relieve symptoms of Chronic Spontaneous Urticaria.
Ligelizumab is approved for use in the following clinical indications:
- Chronic Spontaneous Urticaria (CSU)
72mg, 120mg, 240mg
Subcutaneous
Pharmacodynamics
Ligelizumab is called a second-generation novel anti-IgE monoclonal antibody. It is mostly called as IgG1 anti-IgE monoclonal antibody.
Activity against free serum IgE is the most important mechanism for Ligelizumab. The binding affinity of Ligelizumab for IgE plays an important role in the determination of clinical efficacy. It has a high affinity to the Cε3 domain of IgE. Ligelizumab is said to be a monoclonal antibody with a higher affinity to IgE
Ligelizumab causes inhibition of IgE binding without displacement of IgE bound to the receptor. Compared to Ligelizumab, ligelizumab has been reported to cause 6–9 times higher suppression of allergen-induced skin prick tests. It may have more potency than Ligelizumab in the treatment of chronic spontaneous urticaria.
Pharmacokinetics
In patients suffering from chronic spontaneous urticaria, ligelizumab administered subcutaneously every month for 5 months has been reported to have a dose-response relationship with symptoms.
- Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011; 66:317-330.
- DermNet NZ. Chronic spontaneous urticaria [online] December 2018. Available from: https://dermnetz.org/topics/chronicspontaneous-urticaria
- Grob JJ, Revuz J, Ortonne JP, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289-295.
- Balp MM, Khalil S, Tian H, et al. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2018;32:282-290.
- Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44:1371-1385.
- Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from Ligelizumab. Nat Commun. 2020;11:16
- Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2018;73:1393-1414.
- Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124:2-12.
- Kaplan AP. Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria. Allergy Asthma Proc. 2018;39:184-190.
- Ghazanfar MN, Kibsgaard L, Thomsen SF, et al. Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study. World Allergy Organ J. 2020;13:100097.
- https://go.drugbank.com/drugs/DB11856
- https://www.researchgate.net/publication/334670547_Ligelizumab_for_Chronic_Spontaneous_Urticaria
- https://pubmed.ncbi.nlm.nih.gov/25200415/
- https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ligelizumab
- https://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=12;epage=14;aulast=Godse
- https://www.novartis.com/sites/novartis_com/files/effect-ligelizumab-complete-symptom-control-quality-life-chronic-spontaneous-urticaria.pdf
- https://www.urticariaknowledgecenter.novartis.com/GUF_UCARE/presentations/UCARE 2019/UCARE 2019_Ligelizumab Reduces Rescue_Poster.pdf
